Pharma stock engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, APIs’ and many others jumped 8 percent in the day’s trade upon filing its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA.
With a market capitalization of Rs. 4,683.21 Crores, the shares of Shilpa Medicare Limited were trading at Rs. 478.90 per equity share, up 8.20 percent from its previous day’s close price of Rs. 442.60.
Shilpa Medicare Limited’s wholly owned subsidiary Shilpa Biologicals Pvt Ltd has filed its first Drug Master File of recombinant Human Albumin 20 percent with the USFDA. The Recombinant Human Albumin 20 percent targets to fulfill the growing demand for human serum albumin to deliver current and growing market demand. It is said to be used to treat the blood volume loss.
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20 percent process which is completely Environment friendly, Consistent High-Quality product, Scalable to massive scales, and is cost competitive.
Shilpa Medicare Limited is engaged in the business of manufacturing, sale, and research and development of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations for both domestic and international markets.
As of Q4FY24, Shilpa Medicare Limited generated 62 percent of its revenue from API, 33 percent from Formulations, 4 percent from Biologicals, and 1 percent from Others.
Its revenue from operations grew by 10.67 percent from Rs. 263.56 Crores in Q4FY23 to Rs. 291.69 Crores in Q4FY24, accompanied by a loss of Rs. 8.06 Crores to a profit of Rs. 24.5 Crores.
In terms of Return Ratios, it has reported a return on equity (ROE) of 1.72 percent, a return on capital employed (ROCE) of 5.27 percent, and a debt-to-equity ratio of 0.52.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
